May 23, 2017 7:42 AM ET

Biotechnology

Company Overview of Ichor Medical Systems, Inc.

Company Overview

Ichor Medical Systems, Inc., a biotechnology company, engages in the clinical application and commercialization of electroporation-mediated DNA drug delivery systems. The company offers TriGrid Delivery System for delivery of DNA drugs and vaccines to treat diseases, such as pandemic flu, hepatitis B, HIV, melanoma, and multiple sclerosis. Its system also enables delivery of DNA drugs to address various medical needs in the areas of therapeutic cancer vaccines, therapeutic proteins, and vaccines for serious infectious diseases. The company was founded in 1994 and is based in San Diego, California.

6310 Nancy Ridge Drive

Suite 107

San Diego, CA 92121

United States

Founded in 1994

Phone:

858-550-2022

Fax:

858-550-2092

Key Executives for Ichor Medical Systems, Inc.

Co-Founder, Chief Executive Officer and President
Vice President of Research & Development
Director of Therapeutic Programs
Compensation as of Fiscal Year 2016.

Ichor Medical Systems, Inc. Key Developments

Scancell Holdings plc Announces Extension of Commercial Option Use of Ichormedical Systems

Scancell Holdings plc announced that it has been granted a further extension to its option to license the commercial use of Ichor Medical Systems' (Ichor's) proprietary TriGrid® electroporation delivery system with SCIB1, Scancell's ImmunoBody® vaccine for the treatment of melanoma. Under the terms of the agreed extension, Scancell's license option, which had been due to expire on 13 July 2016, has been extend until 13 July 2018.

FIT Biotech Oy and Ichor Medical Systems Enters into Research Collaboration Agreement

FIT Biotech Oy and Ichor Medical Systems entered into a research collaboration agreement. The purpose of the collaboration is to test FIT Biotech's proprietary GTU® technology in combination with Ichor's TriGrid® electroporation system in order to elicit the endogenous production of protective antibodies for passive immunoprophylaxis. By offering the prospect for rapid and sustained production of highly active antibodies from a recipient's own cells, this approach could provide a new potential avenue to prevent the onset and progression of a wide range of infectious diseases. The ultimate goal of the research is the development of a highly adaptable and cost effective infectious disease product platform capable not only of addressing currently circulating infectious pathogens but also emerging diseases with the potential to cause worldwide pandemias. If the test results are favourable, the partners intend to incorporate FIT Biotech's GTU® technology with Ichor's TriGrid® electroporation system, to be used in further testing within Ichor's internal monoclonal antibody studies as well as other development programs.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3Bar Biologics Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
The Advertising Council, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Ichor Medical Systems, Inc., please visit www.ichorms.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.